What Makes Marion Laboratories Different From Other Pharmaceutical Companies?
If you’re looking for a job at a pharmaceutical company, you’ve probably heard of Marion Laboratories. But what are the qualities that make this company stand out among the hundreds of companies that make identical products? For starters, its work ethic is second to none. With a work ethic that’s second to none, associates at Marion must out-hustle and out-work their competitors to make the company profitable. In fact, this work ethic has earned Marion the title of the industry’s most productive force. Its associates are so motivated that the company ranks first in profits and sales per associate.
The main focus of Marion Pharmaceuticals was developing and marketing drugs for calcium-related ailments. One such drug, Cardizem, was approved by the Food and Drug Administration in 1986 for the treatment of stable and unstable angina. Released in tablet form, the drug helped prevent calcium buildup in artery muscle. However, competition grew as other companies submitted similar compounds to the FDA for approval. As a result, Cardizem remained a niche product and the competition for the product was fierce.
The anti-ulcer drug Carafate is the cornerstone of the Marion Laboratories business. Its introduction in 1981 gave it instant success, capturing 5% of the anti-ulcer drug market. However, the competition is stiff, with generic drugs coming to the market. However, the company has been making some progress, and in the next few years, the company should be able to grow its business without having to worry about piracy or patent infringement.
Carafate is an ulcer drug
When the FDA approved Carafate in 1982, it represented an entirely new type of ulcer drug. By forming a barrier, it prevents further damage to the mucosal tissues. In addition to blocking the action of pepsin and gastric acid, the drug also poses no threat to healthy tissue. It is a relatively new drug that originated in Japan. Tanabe Seiyaku, a pharmaceutical research and development company, has taken a stake in Carafate and pays Marion Laboratories for licensing rights. In 1984, the companies began a joint venture to develop the drug.
Cardizem is the company’s biggest seller
The drug Carafate is one of the top-selling drugs from Marion Laboratories, generating $1 billion in sales since its approval in 1981. The drug forms a protective barrier that blocks the action of pepsin and gastric acid in the crater of an ulcer without harming healthy tissue. The drug originated in the research of Tanabe Seiyaku, which pays licensing fees to the company. In 1984, Marion and Tanabe entered a joint venture to market Tanabe products in the U.S. and Canada.
Carafate is the company’s biggest seller
When its exclusivity period for Cardizem expires in November 1992, Marion Drug Company will face stiff competition from generic drugs. However, the company’s new sustained-release capsule version of the drug, Carafate SR, will offer greater convenience for patients. According to Mehta & Isaly partner Samuel D. Isaly, a drug’s compliance factor is low among patients without symptoms of high blood pressure.
Cardizem is sold worldwide
A pioneer drug, diltiazem hydrochloride, was introduced in 1982 by Marion Merrell Dow under the brand name “Cardizem.” The product was marketed for use in the treatment of neuropathic pain and was available only in pill form. Until 1989, patients were required to take three or four tablets a day. Failure to take a dose could result in an undesirable fluctuation in diltiazem levels in the blood. In 1989, Dow introduced a once-a-day product, which has become the most popular hydrochloride drug in the United States.